Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
OR

NASDAQ · ORTX

Orchard Therapeutics plc

Healthcare · Biotechnology

$16.70

Up+$0.05 (+0.30%)

Updated Aug 23, 2026, 3:27 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
380.11M
P/E ratio
-27.11
Dividend yield
0.00%
52-week range
— – —
Volume
372.35K
Avg. volume
92.98K

Price performance

ORTX price history

1M range · 0 trading sessions · Daily adjusted prices

ORTX does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ORTX news

The latest Smart Investors Daily articles mentioning ORTX.

Stock researchCompany · Overview

ORTX research

Overview

Company profile and research snapshot.

Company profile

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$16.32
Implied upside
—
Analysts
—
ORTX recent ratings
DateFirmRatingTarget
Oct 5, 2023StifelHold—
Aug 9, 2023OppenheimerOutperform—
Jun 27, 2023Cantor FitzgeraldOverweight—
Jun 13, 2023OppenheimerOutperform—
Mar 28, 2023Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jan 25, 2024

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD). The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company’s geographic expansion plans.

GlobeNewswire Inc. · Dec 11, 2023

Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD

BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By